Cargando…
Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials
BACKGROUND: Dopamine agonists (DAs) are a first-line therapy for moderate-to-severe restless legs syndrome (RLS), but these treatments may lead to complications, such as augmentation and impulse control disorders, requiring switching to another therapeutic class. Here we assess efficacy and tolerabi...
Autores principales: | Ondo, William G, Hermanowicz, Neal, Borreguero, Diego García, Jaros, Mark J, Kim, Richard, Shang, Gwendoline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711039/ https://www.ncbi.nlm.nih.gov/pubmed/26788345 http://dx.doi.org/10.1186/s40734-015-0018-3 |
Ejemplares similares
-
Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome
por: Jones, Ruth, et al.
Publicado: (2010) -
Gabapentin enacarbil – clinical efficacy in restless legs syndrome
por: Agarwal, Pinky, et al.
Publicado: (2010) -
Role of gabapentin enacarbil XR in restless legs syndrome
por: Sivam, Sheila, et al.
Publicado: (2012) -
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
por: Burke, Rachel A., et al.
Publicado: (2012) -
Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?
por: Kume, Akito
Publicado: (2014)